遠山 竜也 とおやま たつや 先生

来歴等

略歴

1989年 名古屋市立大学医学部 卒業
1996年 名古屋市立大学 医学博士取得
1996年 カナダ・カルガリー大学 留学
2003年 愛知県がんセンター乳腺科 医長
2005年 名古屋市立大学大学院 医学研究科 腫瘍・免疫外科学分野 助教
2007年 名古屋市立大学大学院 医学研究科 腫瘍・免疫外科学分野 講師
2009年 名古屋市立大学大学院 医学研究科 腫瘍・免疫外科学分野 准教授
2012年 名古屋市立大学大学院 医学研究科 腫瘍・免疫外科学分野 病院教授
2016年 名古屋市立大学大学院 医学研究科 乳腺外科学分野 教授

論文

• No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment. Jpn J Clin Oncol. 39(10):651-6, 2009.

  Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y.

• Prognostic impact of TP53INP1 gene expression in estrogen receptor α-positive breast cancer patients. Jpn J Clin Oncol. 2019 Jun 1;49(6):567-575. doi: 10.1093/jjco/hyz029.

  Nishimoto M, Nishikawa S, Kondo N, Wanifuchi-Endo Y, Hato Y, Hisada T, Dong Y, Okuda K, Sugiura H, Kato H, Takahashi S, Toyama T.

• Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Research 9:R34, 2007.

  Toyama T, Zhenhuan Zhang, Mariko Nishio, Maho Hamaguchi, Naoto Kondo, Hirotaka Iwase, Hiroji Iwata, Satoru Takahashi, Hiroko Yamashita, Yoshitaka Fujii.

• Low Expression of the Snail Gene is a Good Prognostic Factor in Node-Negative Invasive Ductal Carcinomas. Jpn J Clin Oncol 36(6):357-363, 2006

  Toyama T, Zhenhuan Zhang, Hirotaka Iwase, Hiroko Yamashita, Yoshiaki Ando, Maho Hamaguchi, Mitsuhiro Mizutani, Naoto Kondo, Takashi Fujita, Yoshitaka Fujii and Hiroji Iwata,

• Biweekly paclitaxel in patients with metastatic breast cancer, Int J Clin Oncol 8 (6):357-361, 2003

  Toyama T, Yamashita H, Hara H, Sugiura H, Fujii Y, Iwase H,

• p33ING1b stimulates the transcriptional activity of the estrogen receptor alfa via its activation function (AF) 2 domain, J Steroid Biochem Mol Biol 87(1):57-63, 2003

  Toyama T, Iwase H, Yamashita H, Hara Y, Sugiura H, Zhang Z, Fukai I, Miura Y, Riabowol K, Fujii Y,

• Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer, Cancer Letters, 189(1): 97-102, 2003

  Toyama T, Iwase H, Yamashita H, Hara Y, Omoto Y, Sugiura H, Zhang Z and Fujii Y,

• Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer, 8(1):309, 2008.

  Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y.

• Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment , Int J Clin Oncol, 6(6):306-309,2001

  Toyama T, Yamashita H, Hara Y, Hikosaka Y, Kobayashi S, Iwase H

• High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients. Jpn J Clin Oncol. 44(10):889-97, 2014.

  Asano T, Sato S, Yoshimoto N, Endo Y, Hato Y, Dong Yu, Takahashi S, Fujii Y, Toyama T.

• Ezh2 Controls Skin Tolerance through Distinct Mechanisms in Different Subsets of Skin Dendritic Cells. iScience. 21;10:23-39, 2018.

  Loh JT, Lim TJF, Ikumi K, Matoba T, Janela B, Gunawan M, Toyama T, Bunjamin M, Ng LG, Poidinger M, Morita A, Ginhoux F, Yamazaki S, Lam KP, Su IH.

• Regulatory T cells expressing abundant CTLA-4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer. Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32024. [Epub ahead of print]

  Matoba T, Imai M, Ohkura N, Kawakita D, Ijichi K, Toyama T, Morita A, Murakami S, Sakaguchi S, Yamazaki S.

• Effects of serum estradiol and progesterone on estrogen-regulated gene expression in breast cancers of premenopausal patients. Jpn J Clin Oncol. 2018 Nov 5. doi: 10.1093/jjco/hyy156. [Epub ahead of print]

  Wanifuchi-Endo Y, Asano T, Kondo N, Hato Y, Dong Y, Hisada T, Nishikawa S, Kato H, Takahashi S, Okuda K, Yamashita H, Toyama T.

• Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat. 2018 Sep 21. doi: 10.1007/s10549-018-4964-y. [Epub ahead of print]

  Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y.

• A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. Breast Cancer 25(6):729-735, 2018.

  Toyama T, Yoshimura A, Hayashi T, Kobayashi N, Saito K, Tsuneizumi M, Sawaki M, Hattori M, Nakada T, Yokota I, Iwata H.

• Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. JAMA Oncol. 4(7):977-984, 2018.

  Royce M, Bachelot T, Villanueva C, Özgüroglu M, Azevedo SJ, Cruz FM, Debled M, Hegg R, Toyama T, Falkson C, Jeong J, Srimuninnimit V, Gradishar WJ, Arce C, Ridolfi A, Lin C, Cardoso F.

• Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women. Oncotarget. 8(39):65759-65769, 2017.

  Guo J, Sueta A, Nakamura K, Yoshimoto N, Baba M, Ishida N, Hagio K, Toyama T, Iwase H, Tamakoshi A, Yamashita H,

• A randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Sci. 108(5):987-994, 2017.

  Tamura K, Inoue K, Masuda N, Takao S, Kashiwaba M, Tokuda Y, Iwata H, Yamamoto N, Aogi K, Saeki T, Nakayama T, Sato N, Toyama T, Ishida T, Arioka H, Saito M, Ohno S, Yamauchi H, Yamada K, Watanabe J, Ishiguro H, Fujiwara Y.

• Identification of targets of tumor suppressor microRNA-34a using a reporter library system. Proc Natl Acad Sci U S A. 114(15):3927-3932, 2017.

  Ito Y, Inoue A, Seers T, Hato Y, Igarashi A, Toyama T, Taganov KD, Boldin MP, Asahara H.

• HER2 mutation status in Japanese HER2-positive breast cancer patients. Breast Cancer. 23(6):902-907, 2016.

  Endo Y, Dong Y, Kondo N, Yoshimoto N, Asano T, Hato Y, Nishimoto M, Kato H, Takahashi S, Nakanishi R, Toyama T.

• Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients. Int J Clin Oncol. 21(3):539-47, 2016

  Hato Y, Kondo N, Yoshimoto N, Endo Y, Asano T, Dong Y, Nishimoto M, Takahashi S, Fujii Y, Nakanishi R, Toyama T.

• Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 17(1):90-8, 2016.

  Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC study group.

• Immunohistochemical determination of arylamine N-acetyltransferase 1 (NAT1) as the target of miR-1290 and prognostic biomarker of breast cancer. BMC Cancer. 14(1):990, 2014.

  Endo Y, Yamashita H, Takahashi S, Sato S, Yoshimoto N, Asano T, Hato Y, Dong Y, Fujii Y, Toyama T.

• Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer. Proc Natl Acad Sci USA. 111(5):1933-8, 2014.

  Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, Filipovic A, Warner M. Gustafsson JA.

• HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients. Jpn J Clin Oncol. 44(7):619-23. 2014.

  Endo Y, Dong Y, Yoshimoto N, Asano T, Hato Y, Yamashita H, Sato S, Takahashi S, Fujii Y, Toyama T.

• High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol. 42(4):256-63, 2012.

  Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, Takahashi S, Fujii Y, Yamashita H.

• Suppression of ING1 expression in sporadic breast cancer, Oncogene 18(37):5187-5193,1999

  Toyama T，Iwase H，Watson P，Muzik H，Saettler E，Magliocco A，DiFrancesco L，Forsyth P，Garkavtsev I，Kobayashi S，Riabowol K,

• Microsatellite instability in in situ and invasive sporadic breast cancers of Japanese women, Cancer Letters，108(2):205-209, 1996

  Toyama T，Iwase H，Iwata H，Hara Y，Omoto Y，Suchi M，Kato T，Nakamura T，Kobayashi S,

• Microsatellite Instability in sporadic human breast cancers, Int J Cancer，68(4):447-451, 1996

  Toyama T，Iwase H，Yamashita H，Iwata H，Yamashita T，Ito K，Hara Y，Suchi M，Kato T，Nakamura T，Kobayashi S,

• Pathogenesis of thymolipoma：Report of three cases, Surg Today，25(1)：86-88, 1995

  Toyama T，Mizuno T，Masaoka A，Shibata K，Yamakawa Y，Niwa H，Torii K,

その他

• 【受賞】第45回日本癌治療学会総会 優秀演題賞(2007年)

• 【受賞】第６回日本乳癌学会 研究奨励賞(2000年)

• 【ラジオ出演】ラジオNIKKEI（日経ラジオ社）の薬剤師向け専門番組「薬学の時間」（2019/3/7）

• 【インタビュー】読売新聞全国版 医療面「再発乳がん薬物療法の進歩」内にインタビュー記事（2018/8/25）

• 【インタビュー】読売新聞 朝刊「病院の実力：乳がん 編」のインタビュー記事（2016/11/16）

• 【ラジオ出演】CBCラジオの「オトナのクリニック」で「乳がん検診」についてのインタビュー（2016/2/10）

• 【テレビ出演】名古屋テレビ【メ～テレ】の「ドデスカ！」で「乳がん」の解説（2015/9/28）

• 【ラジオ出演】CBCラジオ多田しげおの気分爽快～朝からP．Ｏ．Ｎ、「男性乳がん」についてのインタビュー（2015/2/24）

• 【テレビ出演】名古屋テレビ【メ～テレ】「医ＴＶスペシャル・乳がん治療の現場から」に出演（2014/11/9）

SNS・ブログ等

• その他メディア
  • 名古屋市立大学病院乳腺外科・名古屋市立大学大学院医学研究科乳腺外科分野